Small biotechs who chose to partner with us
Monoclonal antibodies at Corvus
Corvus is a small biotech developing a monoclonal antibody for oncology patients. Lonza started work with available capacity in Singapore and then transferring to Slough, UK. The product is currently in clinical trials.
Protein development at Levicept
Simon Westbrook had an idea for a complex fusion chimera protein he believed could have a profound impact on chronic pain and joint degeneration in osteoarthritis patients. Lonza worked with him early on and the molecule is now in Phase II.
Surrozen – complex bispecific antibodies targeting tissue regeneration
Surrozen’s President & CEO, Craig Parker, discusses how the expertise, resources and flexibility of Lonza have been fundamental in advancing its novel and complex bispecific antibody candidates that target the WNT pathway.
Tuning the Myeloid Compartment with a Best-in-Class CDMO
Alicia Levey and Kiren Khanduja of Pionyr Immunotherapeutics discuss the basis for selection of Lonza to meet Pionyr’s goals to rapidly develop a third lead candidate from the start and to scale-up manufacturing of two clinical-stage immuno-oncol-5ogy treatments after tech transfer.